Related Experiment Video
Updated: Jan 11, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Lipid management for primary and secondary stroke prevention consensus paper of the International Lipid Expert Panel
Maciej Banach1, Peter P Toth2, Hyo-Jeong Ahn3
1Faculty of Medicine, John Paul II Catholic University of Lublin, Lublin, Poland; Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland; Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Insights
Ischemic stroke is a major global health issue. This paper provides practical guidance on lipid management to reduce recurrent stroke risk and complications.
Area of Science:
- Cardiovascular Medicine
- Neurology
- Public Health
Background:
- Ischemic stroke is a leading cause of death and disability globally, with high blood pressure and elevated LDL-C as major risk factors.
- Lipid disorders, including elevated lipoprotein(a), are often undiagnosed or poorly managed, contributing to stroke risk and recurrence.
- Current guidelines for lipid-lowering therapy (LLT) in stroke prevention are inconsistent, and understanding of LLT effects on hemorrhagic stroke and dementia is limited.
Purpose of the Study:
- To provide consistent, practical guidance on lipid targets and treatment pathways for stroke prevention.
- To address the inadequate diagnosis and management of lipid disorders in both primary and secondary stroke prevention.
- To reduce the risk of recurrent ischemic strokes and associated complications through improved lipid management.
Main Methods:
- Consensus paper development.
- Review of current data on stroke epidemiology, risk factors, and lipid management.
- Formulation of evidence-based recommendations for lipid targets and combination therapy.
Main Results:
- Significant proportion of stroke patients receive inadequate or no lipid-lowering therapy.
- High rates of recurrent ischemic stroke within five years, linked to poor lipid management.
- Need for upfront combination LLT to achieve treatment goals promptly.
Conclusions:
- Early and intensive lipid-lowering therapy is crucial for secondary stroke prevention.
- Clear, practical guidance is needed to improve diagnosis and management of lipid disorders in stroke patients.
- Effective lipid management can reduce recurrent ischemic strokes and improve patient outcomes.
Abstract:
Ischemic stroke is a significant global health challenge, accounting for approximately 66 % of all strokes worldwide. Recent data indicates that stroke was the third leading cause of death (10.7 % of all deaths), following ischemic heart disease and COVID-19. In 2021, nearly 94 million people were living with the consequences of a stroke, and about 12 million new cases were reported. Major risk factors for stroke include high systolic blood pressure, exposure to ambient particulate matter, smoking, and elevated levels of low-density lipoprotein cholesterol (LDL-C), with LDL-C contributing to nearly one-third of all ischemic strokes. In primary prevention, many at-risk individuals have undiagnosed or poorly managed lipid disorders, including elevated lipoprotein(a). The challenge persists in secondary prevention, where up to 40 % of individuals at risk of recurrent ischemic stroke experience a recurrence within five years. A key reason for this is the inadequate diagnosis and management of lipid disorders, underscoring the necessity for early and intensive (upfront) combination lipid-lowering therapy (LLT) to meet treatment goals promptly after an event. Unfortunately, data indicates that up to 40 % of post-stroke patients receive no LLT, and many more receive inadequate treatment. Additionally, existing guidelines for LLT in both primary and secondary stroke prevention are often inconsistent and outdated. Similarly, the understanding of the effects of LDL-C and LLT on the risks of haemorrhagic stroke and dementia remains limited, emphasizing the need for clear and practical guidance. Thus, within this Consensus Paper we aimed to provide consistent, easy-to-follow, and practical guidance on lipid targets, along with clear pathways for effectively treating patients with lipid disorders who are at risk for stroke and those who have experienced one. This approach is intended to help reduce the risk of recurrent ischemic strokes and their associated complications.
Related Concept Videos
Atherosclerosis III: Management
Angina IV: Management
Peripheral Artery Disease III: Interprofessional Care
Atherosclerosis IV: Nursing Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease V: Interprofessional Care

